Omnicell Inc
NASDAQ:OMCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (1.5), the stock would be worth $39.31 (9% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.6 | $43.1 |
0%
|
| 3-Year Average | 1.5 | $39.31 |
-9%
|
| 5-Year Average | 1.9 | $49.82 |
+16%
|
| Industry Average | 1.7 | $45.91 |
+7%
|
| Country Average | 2.4 | $64.09 |
+49%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$1.5B
|
/ |
Jan 2026
$1.2B
|
= |
|
|
$1.5B
|
/ |
Dec 2026
$1.3B
|
= |
|
|
$1.5B
|
/ |
Dec 2027
$1.3B
|
= |
|
|
$1.5B
|
/ |
Dec 2028
$1.4B
|
= |
|
|
$1.5B
|
/ |
Dec 2029
$1.4B
|
= |
|
|
$1.5B
|
/ |
Dec 2030
$1.5B
|
= |
|
|
$1.5B
|
/ |
Dec 2031
$1.6B
|
= |
|
|
$1.5B
|
/ |
Dec 2032
$1.6B
|
= |
|
|
$1.5B
|
/ |
Dec 2033
$1.7B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Omnicell Inc
NASDAQ:OMCL
|
1.9B USD | 1.6 | 945.7 | |
| JP |
|
Medical Data Vision Co Ltd
TSE:3902
|
37.9T JPY | 9.7 | 227.5 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 5.4 | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
25.9B USD | 8.1 | 28.5 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
14.2B AUD | 56.6 | 60 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 3 | 20.8 | |
| SE |
|
Sectra AB
STO:SECT B
|
49.7B SEK | 21 | 91.8 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.8B USD | 4.3 | 42.2 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD | 7 | 18.7 | |
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
261.1B INR | 8.7 | 40.3 | |
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR | 11.9 | -328 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Omnicell Inc
Glance View
Omnicell Inc. stands at the intersection of healthcare and technology, sculpting the landscape of medication management systems with its innovative spirit. Founded in 1992, Omnicell has evolved from a small enterprise into a leading provider of automated solutions for medication and supply dispensing, inventory management, and analytics. The company’s core offering, its automated dispensing systems, reshapes how hospitals, pharmacies, and healthcare providers manage medications. By utilizing cutting-edge technology, Omnicell improves efficiency, reduces medication errors, and cuts down on healthcare costs. These systems are embedded in the workflow of healthcare facilities, ensuring that medication management becomes seamless, thus elevating patient safety and clinical outcomes. Revenue streams flow robustly from both product sales and associated services. Omnicell garners income by selling its advanced hardware systems, which include everything from pharmacy carousels to medication robotic systems, and supplements these sales with software solutions that offer predictive analytics and inventory optimization. Beyond the initial sale, a significant part of their business model includes recurring revenue through service contracts, software updates, and customer support. This dual approach not only ensures a steady cash flow but also strengthens customer relationships by consistently providing value over time. As the healthcare industry increasingly leans on technology for streamlined operations and cost management, Omnicell’s strategic positioning allows it to capitalize on the demand for sophisticated medication management solutions.
